If your client has Type 2 diabetes or moderate-to-severe sleep apnea, they actually do not qualify for the Bridge program because their regular Part D or MAPD plan should already cover their GLP-1 medication
From the Q2 earnings call Q&A, here are some remarks from leadership answering questions around durability of obesity segment and GLP-1s: Answer #1 Join the thousands of healthcare professionals who read Hospitalogy Subscribe to get expert analysis on healthcare M&A, strategy, finance, and markets
Clin Nutr ESPEN
The reviewed data show that maternal exposure to GLP-1 agonists causes reduced embryonic-fetal survival, increases in major congenital anomalies, reduced fetal weight/growth, retardation of ossification, irregular ossification and skeletal variants in mice, rats and rabbits
What to Expect: A Realistic Timeline on GLP-1 Medication Weeks 14: Dose escalation begins at 0.25 mg/week
A high-fat diet is associated with endotoxemia that originates from the gut
